$PIRS
PIERIS PHARMACEUTICALS, INC.

2023 Q4 Form 10-Q Financial Statement

#000143774923031957 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $1.299M $19.52M $5.846M
YoY Change -77.78% 263.5% -30.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.327M $6.840M $3.985M
YoY Change -41.61% 73.21% -2.45%
% of Gross Profit
Research & Development $4.454M $9.595M $13.38M
YoY Change -66.71% -29.39% -12.87%
% of Gross Profit
Depreciation & Amortization -$196.0K $740.0K $575.0K
YoY Change -134.09% -3.52% -5.58%
% of Gross Profit
Operating Expenses $6.781M $31.33M $17.37M
YoY Change -60.95% 78.62% -10.68%
Operating Profit -$11.81M
YoY Change -2.97%
Interest Expense $455.0K $549.0K $351.0K
YoY Change 29.63% 127.8% -5950.0%
% of Operating Profit
Other Income/Expense, Net -$538.0K $506.0K -$325.0K
YoY Change 65.54% -30.01% -185.98%
Pretax Income -$4.584M -$10.75M -$8.102M
YoY Change -43.42% 10.41% -15.0%
Income Tax
% Of Pretax Income
Net Earnings -$4.584M -$10.80M -$8.102M
YoY Change -43.42% 11.34% -15.0%
Net Earnings / Revenue -352.89% -55.33% -138.59%
Basic Earnings Per Share -$0.11
Diluted Earnings Per Share -$3.71 -$0.11 -$0.11
COMMON SHARES
Basic Shares Outstanding 98.85M 98.85M 74.41M
Diluted Shares Outstanding 1.236M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.37M $44.80M $59.17M
YoY Change -55.44% -35.84% -49.76%
Cash & Equivalents $17.40M $32.89M $38.64M
Short-Term Investments $8.970M $11.90M $20.53M
Other Short-Term Assets $6.275M $13.30M $8.445M
YoY Change -25.7% 68.18% 28.97%
Inventory
Prepaid Expenses
Receivables $572.0K $1.045M $5.810M
Other Receivables $5.467M $0.00 $0.00
Total Short-Term Assets $38.68M $59.09M $73.42M
YoY Change -47.32% -24.78% -42.47%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $16.99M
YoY Change -100.0% -100.0% -11.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $287.0K $1.369M
YoY Change -100.0% -78.04% -52.86%
Total Long-Term Assets $0.00 $287.0K $22.07M
YoY Change -100.0% -98.61% -14.92%
TOTAL ASSETS
Total Short-Term Assets $38.68M $59.09M $73.42M
Total Long-Term Assets $0.00 $287.0K $22.07M
Total Assets $38.68M $59.38M $95.49M
YoY Change -59.49% -40.12% -37.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.372M $2.816M $4.154M
YoY Change -18.83% -22.66% -51.75%
Accrued Expenses $8.187M $24.50M $11.12M
YoY Change -26.39% 115.25% -25.02%
Deferred Revenue $0.00 $994.0K $20.82M
YoY Change -100.0% -94.63% -17.09%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.92M $28.87M $36.58M
YoY Change -67.41% -13.89% -27.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $30.98M
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $30.98M
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.92M $28.87M $36.58M
Total Long-Term Liabilities $0.00 $0.00 $30.98M
Total Liabilities $11.92M $28.87M $67.56M
YoY Change -82.35% -54.47% -34.28%
SHAREHOLDERS EQUITY
Retained Earnings -$315.0M -$310.4M -$290.4M
YoY Change 8.47% 9.95% 12.93%
Common Stock $98.00K $99.00K $74.00K
YoY Change 32.43% 33.78% -99.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.76M $30.51M $27.93M
YoY Change
Total Liabilities & Shareholders Equity $38.68M $59.38M $95.49M
YoY Change -59.49% -40.12% -37.82%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$4.584M -$10.80M -$8.102M
YoY Change -43.42% 11.34% -15.0%
Depreciation, Depletion And Amortization -$196.0K $740.0K $575.0K
YoY Change -134.09% -3.52% -5.58%
Cash From Operating Activities -$19.67M -$9.720M -$12.93M
YoY Change 52.08% 10.73% 18.17%
INVESTING ACTIVITIES
Capital Expenditures -$9.000K $60.00K -$11.00K
YoY Change -18.18% -276.47% -96.78%
Acquisitions
YoY Change
Other Investing Activities $3.433M -$1.910M $1.096M
YoY Change 213.23% -134.7%
Cash From Investing Activities $3.452M -$1.990M $1.107M
YoY Change 211.83% -136.38% -423.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.00K 0.000 93.00K
YoY Change -83.87% -100.0% -98.1%
NET CHANGE
Cash From Operating Activities -19.67M -9.720M -12.93M
Cash From Investing Activities 3.452M -1.990M 1.107M
Cash From Financing Activities 15.00K 0.000 93.00K
Net Change In Cash -16.20M -11.71M -11.73M
YoY Change 38.09% 286.98% 83.76%
FREE CASH FLOW
Cash From Operating Activities -$19.67M -$9.720M -$12.93M
Capital Expenditures -$9.000K $60.00K -$11.00K
Free Cash Flow -$19.66M -$9.780M -$12.92M
YoY Change 52.14% 11.85% 21.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
CY2021Q2 us-gaap Grants Receivable
GrantsReceivable
14200000 eur
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98851927
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74519103
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15617
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15617
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
15617
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
500000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1600000 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37471
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0784346
dei Entity Address Address Line1
EntityAddressAddressLine1
225 Franklin Street, 26th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
246-8998
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
PIRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
98851927
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32894000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38635000 usd
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
11916000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
20534000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1045000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5810000 usd
CY2023Q3 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
2098000 usd
CY2022Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
0 usd
CY2023Q3 pirs Operating Lease Right Of Use Asset Current
OperatingLeaseRightOfUseAssetCurrent
1984000 usd
CY2022Q4 pirs Operating Lease Right Of Use Asset Current
OperatingLeaseRightOfUseAssetCurrent
0 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9152000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8445000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
59089000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
73424000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16992000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3705000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
287000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1369000 usd
CY2023Q3 us-gaap Assets
Assets
59376000 usd
CY2022Q4 us-gaap Assets
Assets
95490000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2816000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4154000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12292000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
859000 usd
CY2023Q3 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
12764000 usd
CY2022Q4 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
10746000 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
994000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
20824000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
28866000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36583000 usd
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
18734000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12244000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
28866000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
67561000 usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
99000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
74000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
341130000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
318530000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-339000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-254000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310380000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-290421000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
30510000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
27929000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59376000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95490000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15569000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5112000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
37665000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
19760000 usd
CY2023Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
3951000 usd
CY2022Q3 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
258000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
3846000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
296000 usd
CY2023Q3 us-gaap Revenues
Revenues
19520000 usd
CY2022Q3 us-gaap Revenues
Revenues
5370000 usd
us-gaap Revenues
Revenues
41511000 usd
us-gaap Revenues
Revenues
20056000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9595000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13589000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37347000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39602000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6839000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3949000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14526000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12409000 usd
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
14893000 usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
14893000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
31327000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
17538000 usd
us-gaap Operating Expenses
OperatingExpenses
66766000 usd
us-gaap Operating Expenses
OperatingExpenses
52011000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11807000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12168000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-25255000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-31955000 usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
549000 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
241000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1396000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
370000 usd
CY2023Q3 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
0 usd
CY2022Q3 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
1468000 usd
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
3612000 usd
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
4782000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
506000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
723000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
288000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1628000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10752000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9736000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19959000 usd
us-gaap Net Income Loss
NetIncomeLoss
-25175000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-204000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-31000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-159000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-387000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-70000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
74000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
82000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10954000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9837000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20044000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25480000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98852000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74397000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87093000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74080000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
44365000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9736000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-31000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-70000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
974000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40498000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10752000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-204000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
966000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
30510000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
50755000 usd
us-gaap Net Income Loss
NetIncomeLoss
-25175000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-387000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
82000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3453000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
104000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
27929000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19959000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-159000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
74000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2898000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
52000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
30510000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19959000 usd
us-gaap Net Income Loss
NetIncomeLoss
-25175000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2102000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2195000 usd
pirs Operating Lease Right Of Use Asset Accretion
OperatingLeaseRightOfUseAssetAccretion
98000 usd
pirs Operating Lease Right Of Use Asset Accretion
OperatingLeaseRightOfUseAssetAccretion
-0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2898000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3453000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
14893000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
53000 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
299000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
129000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-216000 usd
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
33804000 usd
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
27389000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34150000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46999000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1052000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
24007000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
21900000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
15270000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
43191000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8553000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22343000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
95000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
52000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
104000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19729000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6922000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19781000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7121000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
75000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-7120000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5741000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-69341000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38635000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
117764000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32894000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48423000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
74000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
82000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000 usd
CY2023Q3 pirs Reduction In Workforce Percentage
ReductionInWorkforcePercentage
0.70 pure
CY2023Q3 pirs Reduction In Workforce Cost
ReductionInWorkforceCost
6800000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
44800000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10800000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9700000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis of Presentation and Use of Estimates</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying condensed consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The condensed consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are <em style="font: inherit;">not</em> limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; fair value of assets held for sale; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Credit Risk and Off-Balance Sheet Risk</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has <em style="font: inherit;">no</em> financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimize the exposure to concentration of credit risk. The Company has <em style="font: inherit;">not</em> experienced any credit losses in such accounts and does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does <em style="font: inherit;">not</em> obtain collateral.</p>
CY2023Q3 us-gaap Revenues
Revenues
19520000 usd
CY2022Q3 us-gaap Revenues
Revenues
5370000 usd
us-gaap Revenues
Revenues
41511000 usd
us-gaap Revenues
Revenues
20056000 usd
CY2023Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
17100000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
38700000 usd
CY2021Q2 us-gaap Grants Receivable
GrantsReceivable
17000000 usd
CY2023Q3 pirs Cash Equivalents And Investments
CashEquivalentsAndInvestments
39569000 usd
CY2022Q4 pirs Cash Equivalents And Investments
CashEquivalentsAndInvestments
38152000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
11915000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
11916000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-100000 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
200000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
300000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26639000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9647000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16992000 usd
CY2023Q3 pirs Longlived Assets Heldforsale Net Book Value
LonglivedAssetsHeldforsaleNetBookValue
2098000 usd
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
14900000 usd
CY2023Q3 pirs Longlived Assets Heldforsale Net Book Value
LonglivedAssetsHeldforsaleNetBookValue
2100000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8735000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3015000 usd
CY2023Q3 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
1971000 usd
CY2022Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
5758000 usd
CY2023Q3 pirs Accrued Accounts Payable Current
AccruedAccountsPayableCurrent
1348000 usd
CY2022Q4 pirs Accrued Accounts Payable Current
AccruedAccountsPayableCurrent
1245000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
575000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
483000 usd
CY2023Q3 pirs Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
135000 usd
CY2022Q4 pirs Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
245000 usd
CY2023Q3 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
12764000 usd
CY2022Q4 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
10746000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38800000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98851927
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74519103
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
15617
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
280000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
314000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
862000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
943000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
98000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
148000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
476000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
446000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
378000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
462000 usd
us-gaap Lease Cost
LeaseCost
1338000 usd
us-gaap Lease Cost
LeaseCost
1389000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105 pure
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
500000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1600000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
522000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2087000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2087000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2087000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2087000 usd
CY2023Q3 pirs Lessee Operating Lease Liability To Be Paid Due After Year Four
LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
9565000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18435000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6142000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12293000 usd

Files In Submission

Name View Source Status
0001437749-23-031957-index-headers.html Edgar Link pending
0001437749-23-031957-index.html Edgar Link pending
0001437749-23-031957.txt Edgar Link pending
0001437749-23-031957-xbrl.zip Edgar Link pending
ex_565356.htm Edgar Link pending
ex_565357.htm Edgar Link pending
ex_565358.htm Edgar Link pending
ex_565359.htm Edgar Link pending
ex_587528.htm Edgar Link pending
ex_587529.htm Edgar Link pending
ex_587530.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pirs-20230930.xsd Edgar Link pending
pirs20230930_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
pirs-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pirs-20230930_lab.xml Edgar Link unprocessable
pirs-20230930_pre.xml Edgar Link unprocessable
pirs-20230930_cal.xml Edgar Link unprocessable
pirs20230930_10q_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending